Needham analyst Michael Matson has maintained their neutral stance on MDT stock, giving a Hold rating today.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Michael Matson’s rating is based on a mix of positive and negative indicators for Medtronic. The company’s revenue for the third quarter of fiscal year 2025 fell short of expectations, though earnings per share exceeded consensus. This mixed performance, along with a slowdown in organic growth attributed to inventory reductions in the Medical Surgical segment, contributed to a cautious outlook.
On the positive side, Medtronic’s non-GAAP gross and operating margins showed year-over-year improvement, aided by favorable currency effects. Furthermore, the company exhibited promising growth in its Cardiac Ablation Solutions and has potential growth drivers in Hugo and Symplicity Spyral for the future. These factors collectively support a Hold rating, reflecting a balanced perspective on the company’s near-term and long-term prospects.
Matson covers the Healthcare sector, focusing on stocks such as Hologic, TransMedics Group, and Atricure. According to TipRanks, Matson has an average return of -4.8% and a 40.36% success rate on recommended stocks.